Ya-Pei Liu

1.1k total citations
16 papers, 518 citations indexed

About

Ya-Pei Liu is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Ya-Pei Liu has authored 16 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 11 papers in Virology and 7 papers in Emergency Medicine. Recurrent topics in Ya-Pei Liu's work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (9 papers). Ya-Pei Liu is often cited by papers focused on HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (9 papers). Ya-Pei Liu collaborates with scholars based in United States, United Kingdom and France. Ya-Pei Liu's co-authors include Jean‐Michel Molina, Andrew Cheng, Nicolas Margot, Steven L. Chuck, Edwin DeJesus, Erin Quirk, Anthony LaMarca, Jaime Andrade‐Villanueva, Kristen Andreatta and Lijie Zhong and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Lancet Infectious Diseases and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Ya-Pei Liu

16 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ya-Pei Liu United States 10 465 347 167 74 65 16 518
Marie-Aude Khuong-Josses France 9 530 1.1× 364 1.0× 175 1.0× 120 1.6× 18 0.3× 18 568
Naomi Givens United Kingdom 9 566 1.2× 399 1.1× 200 1.2× 107 1.4× 35 0.5× 17 609
David Piontkowsky United States 12 422 0.9× 269 0.8× 206 1.2× 77 1.0× 20 0.3× 27 458
Awny Farajallah United States 8 599 1.3× 408 1.2× 243 1.5× 85 1.1× 19 0.3× 12 649
Kristen Andreatta United States 13 626 1.3× 493 1.4× 217 1.3× 80 1.1× 83 1.3× 33 651
Martin Gartland United Kingdom 11 794 1.7× 634 1.8× 262 1.6× 117 1.6× 47 0.7× 19 866
Rima Acosta United States 11 474 1.0× 343 1.0× 243 1.5× 60 0.8× 35 0.5× 17 512
David Shamblaw United States 6 341 0.7× 239 0.7× 143 0.9× 48 0.6× 14 0.2× 7 379
Christopher Stone United States 10 672 1.4× 550 1.6× 108 0.6× 147 2.0× 55 0.8× 18 733
C Cohen United States 10 249 0.5× 176 0.5× 79 0.5× 80 1.1× 15 0.2× 18 321

Countries citing papers authored by Ya-Pei Liu

Since Specialization
Citations

This map shows the geographic impact of Ya-Pei Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ya-Pei Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ya-Pei Liu more than expected).

Fields of papers citing papers by Ya-Pei Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ya-Pei Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ya-Pei Liu. The network helps show where Ya-Pei Liu may publish in the future.

Co-authorship network of co-authors of Ya-Pei Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Ya-Pei Liu. A scholar is included among the top collaborators of Ya-Pei Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ya-Pei Liu. Ya-Pei Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ys, Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.. (2019). Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. SHILAP Revista de lepidopterología. 20(3). 73–81. 9 indexed citations
2.
Andreatta, Kristen, Madeleine Willkom, Ross Martin, et al.. (2019). Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. Journal of Antimicrobial Chemotherapy. 74(12). 3555–3564. 49 indexed citations
3.
Liu, Ya-Pei, et al.. (2019). Psathyrellanic Acid, a Monocyclic Diterpenoid From the Basidiomycete Psathyrella candolleana. Natural Product Communications. 14(6). 2 indexed citations
4.
DeJesus, Edwin, Sorana Segal‐Maurer, Moti Ramgopal, et al.. (2018). Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Research and Human Retroviruses. 34(4). 337–342. 67 indexed citations
5.
6.
7.
8.
Gallant, Joel E., Graeme Moyle, Juan Berenguer, et al.. (2016). Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial. Current HIV Research. 15(3). 216–224. 5 indexed citations
9.
Negra, Marinella Della, Marcos Tadeu Nolasco da Silva, Kristen Andreatta, et al.. (2015). Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy. The Pediatric Infectious Disease Journal. 34(4). 398–405. 14 indexed citations
10.
Thompson, Melanie, Javier O Morales-Ramirez, Cheryl McDonald, et al.. (2015). Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations
11.
12.
Post, Frank A., Jonathan Winston, Jaime Andrade‐Villanueva, et al.. (2014). Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(3). 310–313. 11 indexed citations
13.
Elion, Richard, Jean‐Michel Molina, José Ramón Arribas, et al.. (2013). A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 494–497. 33 indexed citations
14.
Hu, Shuai, et al.. (2012). ABA signaling mediated by PYR/PYL/RCAR in plants. Hereditas (Beijing). 34(5). 560–572. 18 indexed citations
15.
Negra, Marinella Della, Marcos Tadeu Nolasco da Silva, Jorge Pinto, et al.. (2012). A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents. The Pediatric Infectious Disease Journal. 31(5). 469–473. 22 indexed citations
16.
Molina, Jean‐Michel, Anthony LaMarca, Jaime Andrade‐Villanueva, et al.. (2011). Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. The Lancet Infectious Diseases. 12(1). 27–35. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie-Aude Khuong-Josses Breakdown of academic impact, for papers by Naomi Givens Breakdown of academic impact, for papers by David Piontkowsky Breakdown of academic impact, for papers by Awny Farajallah Breakdown of academic impact, for papers by Kristen Andreatta Breakdown of academic impact, for papers by Martin Gartland Breakdown of academic impact, for papers by Rima Acosta Breakdown of academic impact, for papers by David Shamblaw Breakdown of academic impact, for papers by Christopher Stone Breakdown of academic impact, for papers by C Cohen
Rankless by CCL
2026